Galen v Ivax: Mucodyne ads found misleading for relying on Allegra et al (Fluifort) data

📊

Key facts

⌄

Case number	AUTH/1907/10/06
Parties	Galen Limited v Ivax Pharmaceuticals UK Limited
Product	Mucodyne (carbocysteine)
Main issue	Citing Allegra et al (2006) (Fluifort/carbocysteine lysine salt monohydrate, once-daily regimen) to support Mucodyne-specific efficacy claims and outcomes
Materials	Three journal advertisements (IV/MD/ADV1/01/06; IV/MD/ADV2/01/06; IV/MD/AD/11/05) and a leavepiece/detail aid (IV/MD/DETAIL/LP/08/05; also referenced as IV/MD/DETAIL/LP/03/06)
Key claims challenged	“Mucodyne reduces the hypersecretion and viscosity of mucus…”; “Use of Mucodyne results in… 43% reduction… 40% reduction… 51% increase…”; “Clears mucus to reduce COPD exacerbations”
Applicable Code year	2003
Breach clauses	7.2, 7.4 and 7.10
Complaint received	02 November 2006
Case completed	10 January 2007
Appeal	No appeal
Sanction	Undertaking received

Download the full case report (PDF)

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

🎬 Expert Video Walkthrough

🎬

Video walkthrough — coming for members

Subscribe now and get expert video analysis for every case as we publish them.

Subscribe — from £299/yr

📋

What happened

⌄

Galen complained about Ivax’s promotion of Mucodyne (carbocysteine), arguing it was inappropriate to cite Allegra et al (2006) to support multiple efficacy claims.
Allegra et al studied Fluifort (carbocysteine lysine salt monohydrate) given once daily at 2700mg (stated as equivalent to 1409mg carbocysteine) to prevent acute exacerbations of chronic obstructive bronchitis.
Mucodyne was licensed at 2250mg daily reducing to 1500mg daily, in divided doses (different dose and dosing schedule).
Materials at issue: three journal advertisements (refs IV/MD/ADV1/01/06, IV/MD/ADV2/01/06, IV/MD/AD/11/05) and a leavepiece/detail aid (ref IV/MD/DETAIL/LP/08/05; also referenced as IV/MD/DETAIL/LP/03/06 in the report).
Key claims (referenced to Allegra et al) included:
- “Mucodyne reduces the hypersecretion and viscosity of mucus, thereby making it easier for the patient to clear mucus from the bronchial tree through expectoration.”
- “Use of Mucodyne results in: Carbocysteine vs placebo n=441, 43% reduction in days with acute illness p<0.01, 40% reduction in antibiotic consumption p<0.02, 51% (over two months) increase in delay to first exacerbation p=0.028.”
- Mucodyne “Clears mucus to reduce COPD exacerbations”.
Galen alleged there were no bridging pharmacokinetic, bioequivalence or clinical efficacy data to justify applying Fluifort results to Mucodyne, making the claims misleading and exaggerating the risk/benefit.
Ivax argued carbocysteine is the active compound in plasma for both products, cited pharmacokinetic comparisons (AUC) and referenced broader evidence (including a Cochrane review) to support similar effects across formulations.

⚖️

Outcome

⌄

The Panel found it misleading to imply Mucodyne would produce the results reported in Allegra et al because Allegra et al studied a different form, dose and dosage schedule and no data were provided to show similarity to Mucodyne.
Breach found for the claim supported by Allegra et al: “Mucodyne reduces the hypersecretion and viscosity of mucus…” (Clause 7.2).
For the presentation of Allegra et al outcomes (43% reduction in days with acute illness; 40% reduction in antibiotic consumption; 51% increase in delay to first exacerbation), the Panel considered the ad implied these were shown for Mucodyne when no Mucodyne data were provided (breaches of Clauses 7.2, 7.4 and 7.10).
For “Clears mucus to reduce COPD exacerbations”, the Panel ruled it was misleading to cite Allegra et al in support of a claim specifically for Mucodyne (breaches of Clauses 7.2, 7.4 and 7.10).
The ruling on “Clears mucus to reduce COPD exacerbations” also applied to two other advertisements and the detail aid that included the same claim.
No breach was ruled for Clauses 7.4 and 7.10 in relation to the “hypersecretion and viscosity” claim (the Panel did not consider the reference necessarily meant the claim was incapable of substantiation or that properties were exaggerated).
No appeal.

🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access

Key facts

What happened

Outcome

Clauses

Unlock the full case analysis

AQP Flagship Path — the complete UK ABPI signatory programme

📰 Weekly PMCPA Case Breakdown